Novacta Biosystems: Overcoming Hospital Based Infection




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Novacta Biosystems: Overcoming Hospital Based Infection
Released on: October 28, 2008. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this programme Fintan Walton talks with Tony Sedgwick, CEO of Novacta Biosystems, a UK-based anti infective therapeutic company.
  • Summary
  • Participants
  • Company
In this programme Fintan Walton talks with Tony Sedgwick, CEO of Novacta Biosystems, a UK-based anti infective therapeutic company. They discuss the company’s strong pedigree and background in genetic engineering, particularly with reference to metabolic engineering and hospital based infections. Tony Sedgwick explains that the company has a dual business model, with the service side providing £1 million a year revenue which enables the company to take their therapeutics all the way to clinical trials without corporate partnerships.
Dr Tony Sedgwick
CEO
Novacta Biosystems

Dr Tony Sedgwick was appointed CEO of Novacta Biosystems, a UK-based anti infective therapeutics company, in September 2007. In the same year he was also made a Non-Executive Director of Innova, a company that supplies reagents and consultancy to the life sciences industry.

Before joining Novacta Dr Sedgwick was CEO of DanioLabs Ltd, a Cambridge University spin-out. Under Tony’s leadership DanioLabs became a neurology/ ophthalmology-focussed pharmaceutical reprofiling company. DanioLabs was acquired by Summit plc in March 2007 for £15 million. Between 2002-2005 he was CEO of Cambridge Biotechnology Ltd (“CBT”), a Parke Davis/Cambridge University spin-out. CBT developed a portfolio of product candidates in the areas of pain, obesity and inflammation. In March 2005, CBT was acquired by Biovitrum AB of Stockholm, and continues to operate as an autonomous business unit on the Babraham Research Campus in Cambridge.

Tony Sedgwick began his commercial career in 1986 at Roche where he held the position of Global Head of Clinical Operations and UK Development Director. He gained his PhD FRCPath from the University of London.
Novacta Biosystems